Date Faxed: May 12, 2004

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 30435.152-US-11	Application Number: 10/756,101
	Applicant: Steven M. Dubinett et al.	
	Filing Date: January 13, 2004	Group Art Unit: 1616

U.S. PATENT DOCUMENTS – COPIES OF DOCUMENTS NOT REQUIRED

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SM	5,767,097	06/16/98	Tarn			
	5,871,723	02/16/99	Strieter et al.			
	6,403,370	06/11/02	Alemany et al.			
	US2002/0034494 A1	03/21/02	Vicari et al.			
	US2003/0008840 A1	01/09/03	Vicari et al.			
	US2003/0138413 A1	07/24/03	Vicari et al.			

FOREIGN PATENTS – COPIES OF DOCUMENTS NOT REQUIRED

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
SM	WO 00/38706	07/06/00	PCT				
SM	WO 96/06169	02/29/96	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **COPIES OF DOCUMENTS NOT REQUIRED**

SM		Arenberg et al., "Interferon-Gamma-Inducible Protein 10 (IP-10) is an Angiostatic Factor that Inhibits Human Non-Small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. Exp. Med., 1996, 184: 981-992.
SM		Arenberg et al., "The Murine CC Chemokine, 6C-kine, Inhibits Tumor Growth and Angiogenesis in a Human Lung Cancer SCID Mouse Model," Cancer Immunol. Immunother., 2001, 49: 587-592

EXAMINER:	DATE CONSIDERED: 2/8/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Date Faxed: May 12, 2004

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 30435.152-US-11	Application Number: 10/756,101
	Applicant: Steven M. Dubinett et al.	
	Filing Date: January 13, 2004	Group Art Unit: 1616

		Baggiolini et al., "Human Chemokines: An Update," Ann. Rev. Immunol., 1997, 15: 675-705
		Banchereau et al., "Dendritic Cells and the Control of Immunity," Nature, 1998, 392(6673): 245-252
		Bellone et al., "Tumor-Associated Transforming Growth Factor-β and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients," Am. J. Pathol., 1999, 155(2): 537-547
		Brunda et al., "Antitumor and Antimetastatic Activity of Interleukin 12 Against Murine Tumors," J. Exp. Med., 1993, 178: 1223-1230
		Chan et al., "Secondary Lymphoid-Tissue Chemokine (SLC) Is Chemotactic for Mature Dendritic Cells," Blood, 1999, 93(11): 3610-3616
		Chu et al., "Examining the Immune Response in Sentinel Lymph Nodes of Mice and Men," Eur. J. Nuc. Med., 1999, 26(Supplement): s50-53
		Cyster, "Chemokines and the Homing of Dendritic Cells to the T Cell Areas of Lymphoid Organs," J. Exp. Med., 1999, 189(3): 447-450
		Dieu et al., "Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," J. Exp. Med., 1998, 188(2): 373-386
		D. Dilloo et al, "Combined chemokine and cytokine gene transfer enhances antitumor immunity", Nature Medicine, Vol. 2, No. 10, October 1996, pages 1090-1095
		S. Dubinett et al., "Gene Therapy for Lung Cancer," Gene Therapy, 1998, 12(3): 569-594
		Fajardo et al., "Transforming Growth Factor β1 Induces Angiogenesis In Vivo With a Threshold Pattern," Lab. Investig., 1996, 74(3): 600-608
		Farber, "Mig and IP-10: CXC Chemokines That Target Lymphocytes," J. Leukoc. Biol., 1997, 61(3): 246-257
		Ferrara, "The Role of Vascular Endothelial Growth Factor in Pathological Angiogenesis" Breast Cancer Res. Treat., 1995, 36: 127-137
		Gabrilovich et al., "Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells," Nat. Med., 1996, 2(10): 1096-1103
		Halak et al., "Tumor-Induced Interleukin-10 Inhibits Type 1 Immune Responses Directed at a Tumor Antigen As Well As a Non-Tumor Antigen Present at the Tumor Site," Cancer Res., 1999, 59: 911-917
		Hedrick et al., "Identification and Characterization of a Novel β Chemokine Containing Six Conserved Cysteines," J. Immunol., 1997, 159: 1589-1593

EXAMINER:	DATE CONSIDERED: 2/8/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 30435.152-US-11

Date Faxed: May 12, 2004

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 30435.152-US-11	Application Number: 10/756,101
	Applicant: Steven M. Dubinett et al.	
	Filing Date: January 13, 2004	Group Art Unit: 1616

GH		Hromas et al., "Isolation and Characterization of Exodus-2, a Novel C-C Chemokine with a Unique 37-Amino Acid Carboxyl-Terminal Extension," J. Immunol., 1997, 159: 2554-2558
		Hu et al., "Gene Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile," J. Immunol., 1998, 161: 3033-3041
		Huang et al., "Non-small Cell Lung Cancer Cyclooxygenase-2-dependent Regulation of Cytokine Balance in Lymphocytes..." Cancer Res., 1998, 58(6): 1208-1216
		Jenh et al., "Cutting Edge: Species Specificity of the CC Chemokine 6Ckine Signaling Through the CXC Chemokine..." J. Immunol., 1999, 162: 3765-3769
		Johnson et al., "Interleukin-12, Dendritic Cells, and the Initiation of Host-Protective Mechanisms Against *Toxoplasma Gondii*," J. Exp. Med., 1997, 186(11): 1799-1802
		Kellermann et al., "The CC Chemokine Receptor-7 Ligands 6Ckine and Macrophage Inflammatory Protein-3β Are Potent Chemoattractants for In Vitro- and In Vivo-Derived Dendritic Cells," J. Immunol., 1999, 162: 3859-3864
		Loetscher et al., "Chemokine Receptor Specific for IP-10 and Mig: Structure, Function, and Expression in Activated T-Lymphocytes," J. Exp. Med., 1996, 184: 963-969
		Luster et al., "IP-10, a -C-X-C- Chemokine, Elicits a Potent Thymus-Dependent Antitumor Response In Vivo," J. Exp. Med., 1993, 178: 1057-1065
		Magdaleno et al., "Cyclin-Dependent Kinase Inhibitor Expression in Pulmonary Clara Cells Transformed with SV40 Large T Antigen in Transgenic Mice," Cell Growth & Diff., 1997, 8(2): 145-155
		Nagira et al., "Molecular Cloning of a Novel Human CC Chemokine Secondary Lymphoid-Tissue Chemokine That Is a Potent Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13," J. Biol. Chem., 1997, 272(31): 19518-19524
		Nanda et al., "Induction of anti-self-immunity to cure cancer: meeting review; gene therapy, adoptive immunotherapy and antitumor recombinant vaccine production (conference report)", abstract, Cell, Vol. 82, No. 1, 1995, pages 13-17. Database Biotechds, Accession Number 1995-12009.
		Ogata et al., "Chemotactic Response Toward Chemokines and its Regulation by Transforming Growth Factor-β1 of Murine Bone Marrow Hematopoietic Progenitor Cell-Derived Different Subset of Dendritic Cells," Blood, 1999, 93(10): 3225-3232
		Sallusto et al., "Rapid and Coordinated Switch in Chemokine Receptor Expression During Dendritic Cell Maturation," Eur. J. Immunol., 1998, 28: 2760-2769
		S. Sharma et al., "Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo," J. of Immunology, 2000, 164: 4558-4563

EXAMINER:	DATE CONSIDERED: 8/9/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 30435.152-US-11

Date Faxed: May 12, 2004

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 30435.152-US-11	Application Number: 10/756,101
	Applicant: Steven M. Dubinett et al.	
	Filing Date: January 13, 2004	Group Art Unit: 1616

SM		Sharma et al., "T Cell-Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC Function," J. Immunol., 1999, 163: 5020-5028
		S. Sharma et al., "Secondary Lymphoid Organ Chemokine Reduces Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma," Cancer Research, 2001, 61: 6406-6412
		Soto et al., "The CC Chemokine 6Ckine Binds the CXC Chemokine Receptor CXCR3," PNAS, USA, 1998, 95(14): 8205-8210
		Sozzani et al., "Cutting Edge: Differential Regulation of Chemokine Receptors During Dendritic Cell Maturation: A model for Their Trafficking Properties," J. Immunol., 1998, 161: 1083-1086
		Stolina et al., "Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Sythesis," J. Immunol., 2000, 164: 361-370
		Strieter et al., "Interferon γ-Inducible Protein 10(IP-10), A Member of the C-X-C Chemokine Family, Is an Inhibitor of Angiogenesis," Biochem. Biophys. Res. Commun., 1995, 210(1): 51-57
		Sun et al., "Interleukin-10 Gene Transfer Activates Interferon-γ and the Interferon-γ-Inducible Genes Gbp-1/Mag-1 and Mig-1 in Mammary Tumors," Int. J. Cancer, 1999, 80: 624-629
		Tanabe et al., "Identification of a New Mouse β-Chemokine, Thymus-Derived Chemotactic Agent 4, with Activity on T Lymphocytes and Mesangial Cells," J. Immunol., 1997, 159: 5671-5679
		Tannenbaum et al., "The CXC Chemokines IP-10 and Mig are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor," J. Immunol., 1998, 161: 927-932
		Tsujii et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells," Cell, 1998, 93: 705-716
		Voest et al., "Inhibition of Angiogenesis In Vivo by Interleukin 12," J. Natl. Cancer Inst., 1995, 87(8): 581-586
		Willimann et al., "The Chemokine SLC is Expressed in T Cell Areas of Lymph Nodes and Mucosal Lymphoid Tissues and Attracts Activated T Cells Via CCR7," Eur. J. Immunol., 1998, 28: 2025-2034
		Yoshida et al., "Secondary Lymphoid-Tissue Chemokine is a Functional Ligand for the CC Chemokine Receptor CCR7," J. Biol. Chem., 1998, 273(12): 7118-7122

EXAMINER:	DATE CONSIDERED: 8/18/08
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

G&C 30435.152-US-11